Myocardial Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 68 Published: March 31, 2022 Report Code: GMDGDHC22099IDB

Myocardial ischemia pipeline market research report provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects.

Key Targets in the Myocardial Ischemia Pipeline Market

The key targets in the myocardial ischemia pipeline market are Adenylate Cyclase Type 5, Fibroblast Growth Factor 4, Gap Junction Alpha 1 Protein, N-Formyl Peptide Receptor 2, N-Formyl Peptide Receptor 3, Nitric Oxide Synthase Inducible, Protein Phosphatase 2A, Receptor Type Tyrosine Protein Phosphatase S, Transient Receptor Potential Cation Channel Subfamily M Member 7, and Vascular Endothelial Growth Factor A.

Key MoA in the Myocardial Ischemia Pipeline Market

The key MoA in the myocardial ischemia pipeline market are Adenylate Cyclase Type 5 Inhibitor, Fibroblast Growth Factor 4 Activator, Gap Junction Alpha 1 Protein Inhibitor, N-Formyl Peptide Receptor 2 Agonist, N-Formyl Peptide Receptor 3 Agonist, Nitric Oxide Synthase Inducible Inhibitor, Protein Phosphatase 2A Inhibitor, Receptor Type Tyrosine Protein Phosphatase S Inhibitor, Transient Receptor Potential Cation Channel Subfamily M Member 7 Blocker, and Vascular Endothelial Growth Factor A Activator.

Key RoA in the Myocardial Ischemia Pipeline Market

The key RoA in the myocardial ischemia pipeline market are  oral, intracardiac, intracoronary, intradermal, intravenous, parenteral, and topical. Oral has the highest number of pipeline products.

Myocardial Ischemia Pipeline Market, by RoA

Myocardial Ischemia Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Myocardial Ischemia Pipeline Market

The key molecule types in the myocardial ischemia pipeline market are small molecule, recombinant protein, gene therapy, peptide, synthetic peptide, cell therapy, and oligonucleotide. Small molecule has the highest number of pipeline products.

Myocardial Ischemia Pipeline Market, by Molecule Types

Myocardial Ischemia Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Myocardial Ischemia Pipeline Market

The key companies in the myocardial ischemia pipeline market are Anagenics Ltd, Angionetics Inc, AstraZeneca Plc, BioCardia Inc, Chrysalis BioTherapeutics Inc, CohBar Inc, Eight Plus One Pharmaceutical Co Ltd.

Market report overview

Key targets Adenylate Cyclase Type 5, Fibroblast Growth Factor 4, Gap Junction Alpha 1 Protein, N-Formyl Peptide Receptor 2, N-Formyl Peptide Receptor 3, Nitric Oxide Synthase Inducible, Protein Phosphatase 2A, Receptor Type Tyrosine Protein Phosphatase S, Transient Receptor Potential Cation Channel Subfamily M Member 7, and Vascular Endothelial Growth Factor A
Key MoA Adenylate Cyclase Type 5 Inhibitor, Fibroblast Growth Factor 4 Activator, Gap Junction Alpha 1 Protein Inhibitor, N-Formyl Peptide Receptor 2 Agonist, N-Formyl Peptide Receptor 3 Agonist, Nitric Oxide Synthase Inducible Inhibitor, Protein Phosphatase 2A Inhibitor, Receptor Type Tyrosine Protein Phosphatase S Inhibitor, Transient Receptor Potential Cation Channel Subfamily M Member 7 Blocker, and Vascular Endothelial Growth Factor A Activator
Key RoA Oral, Intracardiac, Intracoronary, Intradermal, Intravenous, Parenteral, and Topical
Key molecule types Small Molecule, Recombinant Protein, Gene Therapy, Peptide, Synthetic Peptide, Cell Therapy, and Oligonucleotide
Key companies Anagenics Ltd, Angionetics Inc, AstraZeneca Plc, BioCardia Inc, Chrysalis BioTherapeutics Inc, CohBar Inc, Eight Plus One Pharmaceutical Co Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Ischemia (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Ischemia (Cardiovascular)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocardial Ischemia (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocardial Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

  • Anagenics Ltd

    Angionetics Inc

    AstraZeneca Plc

    BioCardia Inc

    Chrysalis BioTherapeutics Inc

    CohBar Inc

    Eight Plus One Pharmaceutical Co Ltd

    Guangzhou Magpie Pharmaceutical Co Ltd

    Imbria Pharmaceuticals Inc

    Lixte Biotechnology Holdings Inc

    NervGen Pharma Corp

    NoNO Inc

    Omniox Inc

    Q BioMed Inc

    Symvivo Inc

    Vasade Biosciences Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Myocardial Ischemia – Overview

Myocardial Ischemia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Myocardial Ischemia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Myocardial Ischemia – Companies Involved in Therapeutics Development

Anagenics Ltd

Angionetics Inc

AstraZeneca Plc

BioCardia Inc

Chrysalis BioTherapeutics Inc

CohBar Inc

Eight Plus One Pharmaceutical Co Ltd

Guangzhou Magpie Pharmaceutical Co Ltd

Imbria Pharmaceuticals Inc

Lixte Biotechnology Holdings Inc

NervGen Pharma Corp

NoNO Inc

Omniox Inc

Q BioMed Inc

Symvivo Inc

Vasade Biosciences Inc

Myocardial Ischemia – Drug Profiles

alferminogene tadenovec – Drug Profile

Product Description

Mechanism Of Action

History of Events

AZD-8601 – Drug Profile

Product Description

Mechanism Of Action

History of Events

BJY-802 – Drug Profile

Product Description

Mechanism Of Action

CardiAMP – Drug Profile

Product Description

Mechanism Of Action

History of Events

CMK-103 – Drug Profile

Product Description

Mechanism Of Action

DT-010 – Drug Profile

Product Description

Mechanism Of Action

Gene Therapy for Myocardial Ischemia – Drug Profile

Product Description

Mechanism Of Action

Humanin – Drug Profile

Product Description

Mechanism Of Action

History of Events

LB-100 – Drug Profile

Product Description

Mechanism Of Action

History of Events

MAN-04 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ninerafaxstat – Drug Profile

Product Description

Mechanism Of Action

NVG-291R – Drug Profile

Product Description

Mechanism Of Action

History of Events

OMX-4.80P – Drug Profile

Product Description

Mechanism Of Action

History of Events

PMC-6 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology – Drug Profile

Product Description

Mechanism Of Action

rusalatide acetate – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Antagonize TRPM7 for Oncology, Ophthalmology, Cardiovascular and Central nervous System Disorders – Drug Profile

Product Description

Mechanism Of Action

XG-19 – Drug Profile

Product Description

Mechanism Of Action

Myocardial Ischemia – Dormant Projects

Myocardial Ischemia – Discontinued Products

Myocardial Ischemia – Product Development Milestones

Featured News & Press Releases

Oct 21, 2021: BioCardia announces first patient treated in CardiAMP cell therapy trial for chronic myocardial ischemia

Jun 22, 2021: BioCardia to present CardiAMP cell therapy clinical trial data at European Society of Cardiology Heart Failure 2021

Feb 20, 2019: Phase 1 data published in Nature Communications show potential of mRNA encoding VEGF-A as a regenerative therapeutic

Jan 09, 2017: Angionetics Research Head Authors Scientific American Article on Therapeutic Angiogenesis as Potential New Treatment Approach for Ischemic Heart Disease

Sep 12, 2016: Angionetics’ Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease

May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities

Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum

Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City

Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology

Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention

Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings

May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy

Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease

Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy

Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Myocardial Ischemia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Myocardial Ischemia – Pipeline by Anagenics Ltd, 2022

Myocardial Ischemia – Pipeline by Angionetics Inc, 2022

Myocardial Ischemia – Pipeline by AstraZeneca Plc, 2022

Myocardial Ischemia – Pipeline by BioCardia Inc, 2022

Myocardial Ischemia – Pipeline by Chrysalis BioTherapeutics Inc, 2022

Myocardial Ischemia – Pipeline by CohBar Inc, 2022

Myocardial Ischemia – Pipeline by Eight Plus One Pharmaceutical Co Ltd, 2022

Myocardial Ischemia – Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, 2022

Myocardial Ischemia – Pipeline by Imbria Pharmaceuticals Inc, 2022

Myocardial Ischemia – Pipeline by Lixte Biotechnology Holdings Inc, 2022

Myocardial Ischemia – Pipeline by NervGen Pharma Corp, 2022

Myocardial Ischemia – Pipeline by NoNO Inc, 2022

Myocardial Ischemia – Pipeline by Omniox Inc, 2022

Myocardial Ischemia – Pipeline by Q BioMed Inc, 2022

Myocardial Ischemia – Pipeline by Symvivo Inc, 2022

Myocardial Ischemia – Pipeline by Vasade Biosciences Inc, 2022

Myocardial Ischemia – Dormant Projects, 2022

Myocardial Ischemia – Dormant Projects, 2022 (Contd..1)

Myocardial Ischemia – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Myocardial Ischemia, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.